| 英文摘要 |
Imipramine, classified as a tricyclic antidepressant (TCA), is predominantly employed to ameliorate depressive symptoms and is also being explored as a potential option for addressing urinary incontinence. Imipramine has been shown to possess inhibitory properties against the growth of oral and lung cancers. However, the potential impact of imipramine on bladder cancer has yet to be conclusively determined. Therefore, the goal of this study is to evaluate the inhibitory effects of imipramine on bladder cancer cells and investigate the potential mechanisms underlying its actions. Bladder cancer MB49 and T24 cells were exposed to imipramine and incubated for 24 and 48 hours. Findings from cell viability assays reveal that imipramine markedly impedes the proliferation of bladder cancer cells. Flow cytometry analysis indicates that imipramine significantly increases the activity of cleaved caspase-3, -8, and -9, while promoting the loss of mitochondrial membrane potential (MMP) and the accumulation of reactive oxygen species (ROS). Constitutive activation of fibroblast growth factor receptor 1 (FGFR1) promotes the growth and invasion of bladder cancer cells. Western blot analysis indicates that imipramine significantly inhibits the phosphorylation of FGFR1 in both MB49 and T24 cells. This study demonstrates that imipramine effectively suppresses the growth of bladder cancer cells while inhibiting the activity of FGFR1. Furthermore, imipramine induces apoptosis through the regulation of both extrinsic and intrinsic pathways in bladder cancer cells. |